Related Experiment Videos

Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors

Insights

Macrophages from regressing Moloney sarcomas can kill tumor cells but this ability is lost quickly in vitro. Bacterial lipopolysaccharide (LPS) can trigger killing in tumor-associated macrophages (TAMs).

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Macrophages (Mphi) play a critical role in tumor immunity.
  • The cytotoxic potential of tumor-associated macrophages (TAMs) is variable and context-dependent.
  • Understanding TAM activation is crucial for developing effective cancer immunotherapies.

Purpose of the Study:

  • To investigate the cytotoxic state of macrophages from Moloney sarcomas.
  • To determine the factors influencing macrophage (Mphi) cytolytic activity in vivo and in vitro.
  • To identify signals that can restore or induce killing in non-cytolytic TAMs.

Main Methods:

  • Explantation and in vitro culture of macrophages from regressing and progressing Moloney sarcomas.
  • Assessment of macrophage (Mphi) cytotoxicity against tumor target cells.
  • Stimulation of macrophages with bacterial lipopolysaccharide (LPS) to evaluate killing capacity.

Main Results:

  • Macrophages from regressing sarcomas exhibited transient in vitro cytotoxicity that rapidly decayed.
  • Macrophages from progressing sarcomas and long-term regressor cultures were non-cytolytic.
  • Non-cytolytic tumor macrophages were highly sensitive to picogram/milliliter concentrations of LPS, inducing killing.
  • Thioglycollate-induced peritoneal macrophages (TG-Mphi) did not exhibit LPS-induced killing.

Conclusions:

  • Tumor-associated macrophages (TAMs) are generally primed in vivo.
  • Macrophages in regressing sarcomas acquire cytolytic activity, which is labile.
  • The inability of progressor TAMs to kill may result from a failure to respond to an in vivo triggering signal, not a lack of activation.

Related Concept Videos